RU96109192A - 4 (-Arylaminomethyl) -2,4-DIHYDRO-PYRAZOL-3-ONE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS OBTAINING, METHOD OF TREATING DISEASES - Google Patents
4 (-Arylaminomethyl) -2,4-DIHYDRO-PYRAZOL-3-ONE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS OBTAINING, METHOD OF TREATING DISEASESInfo
- Publication number
- RU96109192A RU96109192A RU96109192/04A RU96109192A RU96109192A RU 96109192 A RU96109192 A RU 96109192A RU 96109192/04 A RU96109192/04 A RU 96109192/04A RU 96109192 A RU96109192 A RU 96109192A RU 96109192 A RU96109192 A RU 96109192A
- Authority
- RU
- Russia
- Prior art keywords
- dihydro
- oxo
- pyrazol
- ethylanylinomethylene
- methyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 3
- 201000010099 disease Diseases 0.000 title claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 cyano, carboxyl Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 6
- 125000004494 ethyl ester group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 229910052801 chlorine Chemical group 0.000 claims 5
- 239000000460 chlorine Chemical group 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 125000005842 heteroatoms Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 239000005711 Benzoic acid Substances 0.000 claims 3
- 125000005118 N-alkylcarbamoyl group Chemical group 0.000 claims 3
- 125000006307 alkoxy benzyl group Chemical group 0.000 claims 3
- 235000010233 benzoic acid Nutrition 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000005499 phosphonyl group Chemical group 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 2
- PYOKUURKVVELLB-UHFFFAOYSA-N Trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 2
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- WQFLPIUEFLJCQI-UHFFFAOYSA-N 2-[1-(4-acetamidophenyl)-4-[(2-ethylanilino)methylidene]-5-oxopyrazol-3-yl]acetic acid Chemical compound CCC1=CC=CC=C1NC=C1C(CC(O)=O)=NN(C=2C=CC(NC(C)=O)=CC=2)C1=O WQFLPIUEFLJCQI-UHFFFAOYSA-N 0.000 claims 1
- MLPVBIWIRCKMJV-UHFFFAOYSA-N 2-ethylaniline Chemical compound CCC1=CC=CC=C1N MLPVBIWIRCKMJV-UHFFFAOYSA-N 0.000 claims 1
- CWVBHDWXBKCALE-UHFFFAOYSA-N 4-[(2-ethoxyanilino)methylidene]-5-methyl-2-(4-morpholin-4-ylsulfonylphenyl)pyrazol-3-one Chemical compound CCOC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)S(=O)(=O)N2CCOCC2)N=C1C CWVBHDWXBKCALE-UHFFFAOYSA-N 0.000 claims 1
- HKCYNIJNRPAVGT-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-methyl-2-[3-(2H-tetrazol-5-yl)phenyl]pyrazol-3-one Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=C(C=CC=2)C=2NN=NN=2)N=C1C HKCYNIJNRPAVGT-UHFFFAOYSA-N 0.000 claims 1
- MBVIGYDIKMKCFH-UHFFFAOYSA-N 4-[(2-ethylanilino)methylidene]-5-propyl-2-[4-(2H-tetrazol-5-yl)phenyl]pyrazol-3-one Chemical compound CCCC1=NN(C=2C=CC(=CC=2)C=2NN=NN=2)C(=O)C1=CNC1=CC=CC=C1CC MBVIGYDIKMKCFH-UHFFFAOYSA-N 0.000 claims 1
- FCISBLOHCPTKJZ-UHFFFAOYSA-N 4-[3-methyl-5-oxo-4-[(2-prop-2-ynoxyanilino)methylidene]pyrazol-1-yl]benzoic acid Chemical compound CC1=NN(C=2C=CC(=CC=2)C(O)=O)C(=O)C1=CNC1=CC=CC=C1OCC#C FCISBLOHCPTKJZ-UHFFFAOYSA-N 0.000 claims 1
- IIXKRFSYQGKQIN-UHFFFAOYSA-N 4-[3-methyl-5-oxo-4-[(2-propoxyanilino)methylidene]pyrazol-1-yl]benzoic acid Chemical compound CCCOC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)C(O)=O)N=C1C IIXKRFSYQGKQIN-UHFFFAOYSA-N 0.000 claims 1
- YFKFRBFVAXZNIP-UHFFFAOYSA-N 4-[3-methyl-5-oxo-4-[[2-(trifluoromethyl)anilino]methylidene]pyrazol-1-yl]benzoic acid Chemical compound CC1=NN(C=2C=CC(=CC=2)C(O)=O)C(=O)C1=CNC1=CC=CC=C1C(F)(F)F YFKFRBFVAXZNIP-UHFFFAOYSA-N 0.000 claims 1
- PTWLOEKMJWYQPM-UHFFFAOYSA-N 4-[4-[(2-ethoxyanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]-N,N-diethylbenzenesulfonamide Chemical compound CCOC1=CC=CC=C1NC=C1C(=O)N(C=2C=CC(=CC=2)S(=O)(=O)N(CC)CC)N=C1C PTWLOEKMJWYQPM-UHFFFAOYSA-N 0.000 claims 1
- QIJCXMVWZZTGAX-UHFFFAOYSA-N 4-[4-[(2-ethoxyanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]-N-ethylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1N(N=C1C)C(=O)C1=CNC1=CC=CC=C1OCC QIJCXMVWZZTGAX-UHFFFAOYSA-N 0.000 claims 1
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N Cyclic guanosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N Methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 claims 1
- NJJLXKYBLPJDTL-UHFFFAOYSA-N N,N-diethyl-4-[4-[(2-methoxyanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N(CC)CC)=CC=C1N(N=C1C)C(=O)C1=CNC1=CC=CC=C1OC NJJLXKYBLPJDTL-UHFFFAOYSA-N 0.000 claims 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 claims 1
- PKOIASMLSYQRDB-UHFFFAOYSA-N N-[3-[4-[(2-ethylanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]phenyl]-2,2,2-trifluoroacetamide Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=C(NC(=O)C(F)(F)F)C=CC=2)N=C1C PKOIASMLSYQRDB-UHFFFAOYSA-N 0.000 claims 1
- PCLANTAXXGOYCJ-UHFFFAOYSA-N N-[3-[4-[(2-ethylanilino)methylidene]-3-methyl-5-oxopyrazol-1-yl]phenyl]methanesulfonamide Chemical compound CCC1=CC=CC=C1NC=C1C(=O)N(C=2C=C(NS(C)(=O)=O)C=CC=2)N=C1C PCLANTAXXGOYCJ-UHFFFAOYSA-N 0.000 claims 1
- HSLQSUQWPOWTJU-UHFFFAOYSA-N N-[3-[4-[(2-ethylanilino)methylidene]-5-oxo-3-propylpyrazol-1-yl]phenyl]methanesulfonamide Chemical compound CCCC1=NN(C=2C=C(NS(C)(=O)=O)C=CC=2)C(=O)C1=CNC1=CC=CC=C1CC HSLQSUQWPOWTJU-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 150000001448 anilines Chemical class 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000000875 corresponding Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- GFAUNYMRSKVDJL-UHFFFAOYSA-N formyl chloride Chemical compound ClC=O GFAUNYMRSKVDJL-UHFFFAOYSA-N 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical group [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 1
- 101710031992 pRL90232 Proteins 0.000 claims 1
- 101710035540 plaa2 Proteins 0.000 claims 1
- 239000010802 sludge Substances 0.000 claims 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims 1
- BSUNTQCMCCQSQH-UHFFFAOYSA-N triazine Chemical compound C1=CN=NN=C1.C1=CN=NN=C1 BSUNTQCMCCQSQH-UHFFFAOYSA-N 0.000 claims 1
- 0 *C(C(C1=O)=CNC2=CN(*)CC=C2)=NN1I* Chemical compound *C(C(C1=O)=CNC2=CN(*)CC=C2)=NN1I* 0.000 description 1
Claims (9)
где R1 - бензил, алкоксибензил с 1 - 3 С-атомами в алкильной части, фенил, незамещенный или замещенный однократно - трехкратно амино-группой, ацилом, галогеном, нитро, CN, AO-, карбоксилом, сульфонилом, A-O-CO-, A-CO-NH, A-CO-NA-, карбамоилом, N-алкилкарбамоилом, N, N-диалкилкарбамоилом (с 1 - 6 С-атомами в алкильной части), A-O-CO-NH-, A-O-CO-NA-, A-SO2-, SO2NR4R5 (R4 и R5 могут представлять H или алкил с 1 - 6 С-атомами или R4R5 представляют 5- или 6-членное кольцо, на выбор с другими гетероатомами, как N, S, O, которое может быть замещено через A), A-CO-NH-SO2-, A-CО-NA-SO2-, A-SO2-NH-, A-SO2-NA, (A-SO2-)2N-. тетразолилом или фосфонилом, или пиридил;
R2 - алкил с 1 - 5 С-атомами, алкоксикарбонилалкил, гидроксиалкил, гидроксикарбонилалкил;
R3 - водород, алкил с 1 - 5 С-атомами с прямой или разветвленной цепью, алкокси 1 - 5 С-атомами с прямой или разветвленной цепью, замещенный фтором или хлором алкил, аминоалканоил, аминоалкил, карбамоил, SO2NR4R5 (R4 и R5 представляют H, алкил с 1 - 6 С-атомами или NR4R5 представляет 5- или 6-членное кольцо, на выбор с другими гетероатомами, как N, S, O, которое может быть замещено через А);
А - алкил с 1 - 6 С-атомами с прямой или разветвленной цепью, замещенный фтором или хлором алкил с 1 - 6 С-атомами с прямой или разветвленной цепью или их соли.1. 4- (arylaminomethylene) -2,4-dihydropyrazol-3-ones of the general formula I
where R 1 is benzyl, alkoxybenzyl with 1 to 3 C-atoms in the alkyl part, phenyl, unsubstituted or substituted once - three times by an amino group, acyl, halogen, nitro, CN, AO-, carboxyl, sulfonyl, AO-CO-, A-CO-NH, A-CO-NA-, carbamoyl, N-alkylcarbamoyl, N, N-dialkylcarbamoyl (with 1-6 C-atoms in the alkyl part), AO-CO-NH-, AO-CO-NA- A-SO 2 -, SO 2 NR 4 R 5 (R 4 and R 5 can represent H or alkyl with 1-6 C atoms or R 4 R 5 represent a 5- or 6-membered ring, optionally with other heteroatoms as N, S, O, which can be substituted via A), A-CO-NH-SO 2 -, A-CO-NA-SO 2 -, A-SO 2 -NH-, A-SO 2 -NA , (A-SO 2 -) 2 N-. tetrazolyl or phosphonyl, or pyridyl;
R 2 is alkyl with 1-5 C-atoms, alkoxycarbonylalkyl, hydroxyalkyl, hydroxycarbonylalkyl;
R 3 is hydrogen, alkyl with 1-5 C-atoms with a straight or branched chain, alkoxy 1-5 C-atoms with a straight or branched chain, substituted by fluorine or chlorine alkyl, aminoalkanoyl, aminoalkyl, carbamoyl, SO 2 NR 4 R 5 (R 4 and R 5 represent H, alkyl with 1-6 C-atoms or NR 4 R 5 represents a 5- or 6-membered ring, optionally with other heteroatoms like N, S, O, which can be substituted through A );
A is alkyl with 1-6 C-atoms with a straight or branched chain, substituted by fluorine or chlorine alkyl with 1-6 C-atoms with a straight or branched chain or their salt.
R2 - гидроксиалкил;
R3 - водород или алкил с 1 - 5 С-атомами с прямой или разветвленной цепью, алкокси с 1 - 5 С-атомами с прямой или разветвленной цепью, замещенный фтором или хлором алкил;
А - алкил с 1 - 6 С-атомами с прямой или разветвленной цепью, замещенный фтором или хлором алкил с 1 - 6 С-атомами с прямой или разветвленной цепью,
или их соли.2. Compounds of general formula according to claim 1, where R 1 denotes benzyl, alkoxybenzyl with 1-3 carbon atoms in the alkyl part, phenyl, unsubstituted or substituted once - three times amino, halogen, nitro, cyano, carboxyl, AO-CO- , A-CO-NH-, A-CO-NA-, carbamoyl, N-alkylcarbamoyl, N, N-dialkylcarbamoyl (with 1-6 C-atoms in the alkyl part) A-SO 2 -NH-, A-SO 2 -NA, aminoacyl, HSO 3 , SO 2 NR 4 R 5 (R 4 and R 5 are H or alkyl with 1-6 C atoms or NR 4 R 5 is a 5- or 6-membered ring, other hetero atoms choose as N, S, O, which can be substituted via A), A-CO-NH-SO 2 -, A-CO-NH-SO 2 -tetrazol pyridyl sludge or phosphonyl;
R 2 is hydroxyalkyl;
R 3 is hydrogen or alkyl with 1-5 C-atoms with a straight or branched chain, alkoxy with 1 to 5 C-atoms with a straight or branched chain, substituted by fluorine or chlorine alkyl;
A is alkyl with 1-6 C-atoms with a straight or branched chain, substituted by fluorine or chlorine alkyl with 1-6 C-atoms with a straight or branched chain,
or their salts.
R2 - H3C-O-CO-CH2-;
R3 - аминоалкил, аминоалканоил, сульфонамидо (с SO2NR4R5, причем R4 и R5 могут обозначать водород или алкил с 1 - 6 С-атомами или NR4R5 представляет 5- или 6-членное кольцо, на выбор с другими гетероатомами, как N, S, O);
А - алкил с 1 - 6 С-атомами с прямой или разветвленной цепью, замещенный фтором или хлором алкил с 1 - 6 С-атомами с прямой или разветвленной цепью, или их соли.3. Compounds of general formula according to claim 1, where R 1 denotes benzyl, alkoxybenzyl with 1-3 carbon atoms in the alkyl part, phenyl, unsubstituted or substituted once - three times through A-CO-NH-, A-CO-NA- , N-alkylcarbamoyl, N, N-dialkylcarbamoyl (with 1-6 C-atoms in the alkyl part), A-CO-NH-SO 2 -, A-CO-NA-SO 2 -, aminoacyl, sulfonyl, SO 2 NR 4 R 5 (R 4 and R 5 denote hydrogen or alkyl with 1-6 C-atoms or NR 4 R 5 represents a 5- or 6-membered ring, optionally with other heteroatoms like N, S, O, which can be substituted by A), acylsulfonamido, tetrazolyl or phosphonyl, pyridyl;
R 2 - H 3 CO-CO-CH 2 -;
R 3 - aminoalkyl, aminoalkanoyl, sulfonamido (with SO 2 NR 4 R 5 , and R 4 and R 5 can be hydrogen or alkyl with 1-6 carbon atoms or NR 4 R 5 is a 5- or 6-membered ring, choice with other heteroatoms like N, S, O);
A is alkyl with 1-6 C-atoms with a straight or branched chain, substituted by fluorine or chlorine alkyl with 1-6 C-atoms with a straight or branched chain, or their salt.
сложный метиловый эфир 3-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-фенил)-карбаминовой кислоты;
4-((2-этоксианилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-N-этилбензолсульфонамид;
сложный этиловый эфир 2-(1-(4-(N, N-диэтилсульфомоил)-фенил)-4-((2-этиланилино)-метилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(1-(4-(N, N-диэтилсульфамоил)-фенил)-4-((2-этоксиланилино)-метилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(1-(4-ацетамидофенил)-4-((2-этиланилино)-метилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(4-((2-этиланилино)-метилен)-4,5-дигидро-5-оксо-1-(4-трифторацетамидофенил)-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(1-(4-этоксикарбониламинофенил)-4-((2-этиланилино)-метилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(4-((2-этиланилинометилен)-4,5-дигидро-1-(4-метансульфонамидофенил)-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
N-(3-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-5Н-пиразол-1-ил)-фенил)-ацетамид;
N, N-диэтил-4-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-бензолсульфонамид;
N-этил-4-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-бензолсульфонамид;
4-(2-этоксианилинометилен)-2,4-дигидро-5-метил-2-(4-(4-морфолинилсульфонил)-фенил)-3Н-пиразол-3-он;
4-(2-этиланилинометилен)-2,4-дигидро-5-метил-2-(4-(4-метил-1-пиперазинилсульфонил)-фенил)-3Н-пиразол-3-он;
N-(3-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-фенил)-метансульфонамид;
N-(3-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-фенил)-трифторацетамид;
N-(4-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-фенил-N-метилсульфонилметансульфонамид;
N, N-диэтил-4-(4,5-дигидро-4-(2-этоксианилинометилен)-3-метил-5-оксо-1Н-пиразол-1-ил)-бензолсульфонамид;
N, N-диэтил-4-(4,5-дигидро-4-(2-метоксианилинометилен)-3-метил-5-оксо-1Н-пиразол-1-ил)-бензолсульфонамид;
3-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-3-пропил-1Н-пиразол-1-ил)-бензолсульфокислота;
4-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-3-пропил-1Н-пиразол-1-ил)-бензолсульфокислота;
сложный этиловый эфир 2-(4-(2-этиланилинометилен)-4,5-дигидро-1-(4-нитрофенил)-5-оксо-1Н-пиразол-1-ил)-уксусной кислоты;
4-(4-(2-этиланилинометилен)-4,5-дигидро5-оксо-3-пропил-1Н-пиразол-1-ил)-бензойная кислота;
4-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-N-гексилбензамид;
4-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-бензамид;
N, N-диэтил-4-(4-(2-этиланилинометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-бензамид;
4-(2-этиланилинометилен)-2,4-дигидро-5-пропил-2-(4-пиридил)-3Н-пиразо- л-3-он;
N, N-диэтил-4-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-3-пропил-1Н-пиразол-1-ил)-бензамид;
4-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-3-пропил-1Н-пиразол-1-ил)-N-гексилбензамид;
4-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-3-пропил-1Н-пиразол-1-ил)-бензамид;
4-(2-этиланилинометилен)-2,4-дигидро-5-пропил-2-(4-(1Н-тетразол-5-ил)-фенил)-3Н-пиразол-3-он;
4-(2-этиланилинометилен)-2,4-дигидро-5-метил-2-(3-(1Н-тетразол-5-ил)- фенил)-3Н-пиразол-3-он;
4-(4,5-дигидро-3-метил-5-оксо-4-(2-трифторметиланилинометилен)-1Н-пиразол-1-ил)-бензойная кислота;
4-(4-(2-этиланилинометилен)-3-этоксикарбонилметил-4,5-дигидро-5-оксо-1Н-пиразол-1-ил)-бензойная кислота;
4-(4,5-дигидро-3-метил-5-оксо-4-(2-(2-пропинилокси)-анилино-метилен)-1Н-пиразол-1-ил)-бензойная кислота;
4-(4,5-дигидро-3-метил-5-оксо-4-(2-пропоксианилинометилен)-1Н-пиразол-1-ил)-бензойная кислота;
4-(4,5-дигидро-4-(2-изопропиланилинометилен)-3-метил-5-оксо-1Н-пиразол-1-ил)-бензойная кислота;
3-(4-(2-этиланилинометиленаминометилен)-4,5-дигидро-3-метил-5-оксо-1Н-пиразол-1-ил)-бензолсульфонамид;
сложный этиловый эфир 2-(1-(4-метоксикарбониламинофенил)-4-((2-этиланилино)-метилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(1-(4-(N, N-диэтилсульфамоил)-фенил-4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(1-(4-(N, N-диэтилсульфамоил)-фенил)-4-(2-этоксианилинометилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(1-(4-ацетамидофенил)-4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-1-(4-трифторацетамидофенил)-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(4-(2-этиланилинометилен)-4,5-дигидро-1-(4-метоксикарбониламинофенил)-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(4-(2-этиланилинометилен)-4,5-дигидро-1-(4-метансульфонамидофенил)-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
сложный этиловый эфир 2-(1-(4-ацетамидофенил)-4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты;
2-(4-(2-этиланилинометилен)-4,5-дигидро-1-(4-метоксикарбониламинофенил)-5-оксо-1Н-пиразол-3-ил)-уксусная кислота;
N-(3-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-3-пропил-1Н-пиразол-1-ил)-фенил)-метансульфонамид;
N-(3-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-3-пропил-1Н-пиразол-1-ил)-ацетамид;
сложный этиловый эфир N-(3-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-3-пропил-1Н-пиразол-1-ил)-фенил)-карбаминовой кислоты;
сложный этиловый эфир 2-(4-(2-этиланилинометилен)-4,5-дигидро-5-оксо-1-(3-трифторацетамидофенил)-1Н-пиразол-1-ил)-уксусной кислоты;
сложный этиловый эфир 2-(4-(2-этиланилинометилен)-4,5-дигидро-1-(3-метансульфонамидофенил)-5-оксо-1Н-пиразол-3-ил)-уксусной кислоты.4. Connection in one of the paragraphs.1 - 3, selected from the group;
3- (4- (2-ethylanylinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) phenyl) -carbamic acid methyl ester;
4 - ((2-ethoxyanilinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazole-1-yl) -N-ethylbenzenesulfonamide;
ethyl 2- (1- (4- (N, N-diethylsulfomoyl) -phenyl) -4 - ((2-ethylanilino) -methylene) -4,5-dihydro-5-oxo-1H-pyrazole-3- yl) acetic acid;
ethyl ester 2- (1- (4- (N, N-diethylsulfamoyl) -phenyl) -4 - ((2-ethoxylanilino) -methylene) -4,5-dihydro-5-oxo-1H-pyrazole-3- yl) acetic acid;
ethyl ester of 2- (1- (4-acetamidophenyl) -4 - ((2-ethylanilino) -methylene) -4,5-dihydro-5-oxo-1H-pyrazol-3-yl) acetic acid;
ethyl ester of 2- (4 - ((2-ethylaniline) -methylene) -4,5-dihydro-5-oxo-1- (4-trifluoroacetamidophenyl) -1H-pyrazol-3-yl) acetic acid;
ethyl 2- (1- (4-ethoxycarbonylaminophenyl) -4 - ((2-ethylanilino) methylene) -4,5-dihydro-5-oxo-1H-pyrazol-3-yl) acetic acid ethyl ester;
ethyl ester of 2- (4 - ((2-ethylanylinomethyl) -4,5-dihydro-1- (4-methanesulfonamidophenyl) -5-oxo-1H-pyrazol-3-yl) acetic acid;
N- (3- (4- (2-ethylanilinomethylene) -4,5-dihydro-3-methyl-5-oxo-5H-pyrazol-1-yl) -phenyl) -acetamide;
N, N-diethyl-4- (4- (2-ethylanylinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) -benzenesulfonamide;
N-ethyl-4- (4- (2-ethylanylinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) -benzenesulfonamide;
4- (2-ethoxyanilinomethylene) -2,4-dihydro-5-methyl-2- (4- (4-morpholinylsulfonyl) -phenyl) -3H-pyrazol-3-one;
4- (2-ethylanylinomethylene) -2,4-dihydro-5-methyl-2- (4- (4-methyl-1-piperazinylsulfonyl) -phenyl) -3H-pyrazole-3-one;
N- (3- (4- (2-ethylanilinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) -phenyl) -methanesulfonamide;
N- (3- (4- (2-ethylanilinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) -phenyl) -trifluoroacetamide;
N- (4- (4- (2-ethylanylinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) -phenyl-N-methylsulfonylmethanesulfonamide;
N, N-diethyl-4- (4,5-dihydro-4- (2-ethoxyanilinomethylene) -3-methyl-5-oxo-1H-pyrazol-1-yl) -benzenesulfonamide;
N, N-diethyl-4- (4,5-dihydro-4- (2-methoxyanilinomethylene) -3-methyl-5-oxo-1H-pyrazol-1-yl) -benzenesulfonamide;
3- (4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-3-propyl-1H-pyrazol-1-yl) benzene sulfonic acid;
4- (4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-3-propyl-1H-pyrazol-1-yl) benzene sulfonic acid;
2- (4- (2-ethylanylinomethylene) -4,5-dihydro-1- (4-nitrophenyl) -5-oxo-1H-pyrazol-1-yl) acetic acid ethyl ester;
4- (4- (2-ethylanylinomethylene) -4,5-dihydro5-oxo-3-propyl-1H-pyrazole-1-yl) benzoic acid;
4- (4- (2-ethylanylinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) -N-hexylbenzamide;
4- (4- (2-ethylanylinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazole-1-yl) -benzamide;
N, N-diethyl-4- (4- (2-ethylanylinomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) -benzamide;
4- (2-ethylanylinomethylene) -2,4-dihydro-5-propyl-2- (4-pyridyl) -3H-pyrazol-3-one;
N, N-diethyl-4- (4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-3-propyl-1H-pyrazol-1-yl) -benzamide;
4- (4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-3-propyl-1H-pyrazol-1-yl) -N-hexylbenzamide;
4- (4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-3-propyl-1H-pyrazole-1-yl) benzamide;
4- (2-ethylanilinomethylene) -2,4-dihydro-5-propyl-2- (4- (1H-tetrazol-5-yl) -phenyl) -3H-pyrazol-3-one;
4- (2-ethylanilinomethylene) -2,4-dihydro-5-methyl-2- (3- (1H-tetrazol-5-yl) -phenyl) -3H-pyrazol-3-one;
4- (4,5-dihydro-3-methyl-5-oxo-4- (2-trifluoromethylanilinomethylene) -1H-pyrazol-1-yl) benzoic acid;
4- (4- (2-ethylanylinomethylene) -3-ethoxycarbonylmethyl-4,5-dihydro-5-oxo-1H-pyrazol-1-yl) benzoic acid;
4- (4,5-dihydro-3-methyl-5-oxo-4- (2- (2-propynyloxy) -anilino-methylene) -1H-pyrazol-1-yl) benzoic acid;
4- (4,5-dihydro-3-methyl-5-oxo-4- (2-propoxyanilinomethylene) -1H-pyrazol-1-yl) benzoic acid;
4- (4,5-dihydro-4- (2-isopropylanophenylmethylene) -3-methyl-5-oxo-1H-pyrazol-1-yl) benzoic acid;
3- (4- (2-ethylanylinomethylene-aminomethylene) -4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl) -benzenesulfonamide;
ethyl 2- (1- (4-methoxycarbonylaminophenyl) -4 - ((2-ethylanilino) -methylene) -4,5-dihydro-5-oxo-1H-pyrazol-3-yl) acetic acid ethyl ester;
ethyl 2- (1- (4- (N, N-diethylsulfamoyl) -phenyl-4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-1H-pyrazol-3-yl) acetic acid ethyl ester ;
ethyl 2- (1- (4- (N, N-diethylsulfamoyl) -phenyl) -4- (2-ethoxyanilinomethylene) -4,5-dihydro-5-oxo-1H-pyrazol-3-yl) acetic ethyl ester acids;
ethyl 2- (1- (4-acetamidophenyl) -4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-1H-pyrazol-3-yl) acetic acid ethyl ester;
2- (4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-1- (4-trifluoroacetamidophenyl) -1H-pyrazol-3-yl) acetic acid ethyl ester;
ethyl 2- (4- (2-ethylanylinomethylene) -4,5-dihydro-1- (4-methoxycarbonylaminophenyl) -5-oxo-1H-pyrazol-3-yl) acetic acid ethyl ester;
2- (4- (2-ethylanylinomethylene) -4,5-dihydro-1- (4-methanesulfonamidophenyl) -5-oxo-1H-pyrazol-3-yl) acetic acid ethyl ester;
ethyl 2- (1- (4-acetamidophenyl) -4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-1H-pyrazol-3-yl) acetic acid ethyl ester;
2- (4- (2-ethylanylinomethylene) -4,5-dihydro-1- (4-methoxycarbonylaminophenyl) -5-oxo-1H-pyrazol-3-yl) acetic acid;
N- (3- (4- (2-ethylanilinomethylene) -4,5-dihydro-5-oxo-3-propyl-1H-pyrazol-1-yl) -phenyl) -methanesulfonamide;
N- (3- (4- (2-ethylanilinomethylene) -4,5-dihydro-5-oxo-3-propyl-1H-pyrazol-1-yl) -acetamide;
ethyl ester of N- (3- (4- (2-ethylanilinomethylene) -4,5-dihydro-5-oxo-3-propyl-1H-pyrazol-1-yl) -phenyl) -carbamic acid;
2- (4- (2-ethylanylinomethylene) -4,5-dihydro-5-oxo-1- (3-trifluoroacetamidophenyl) -1H-pyrazol-1-yl) acetic acid ethyl ester;
ethyl ester of 2- (4- (2-ethylanylinomethylene) -4,5-dihydro-1- (3-methanesulfonamidophenyl) -5-oxo-1H-pyrazol-3-yl) acetic acid.
где R1 и R2 имеют указанные в пп.1 - 3 или 5 значения, превращают с дающими формальдегид группами, из группы триазина, диметилформамида, диметилформамиддиметилацеталя, реактива Гольда, хлорангидрида муравьиной кислоты, формамида или алкильных производных формамида с 1 - 6 С-атомами в алкиле или с соединениями группы триалкилортоформиатов, предпочтительно триметилортоформиата, до соединений общей формулы IIa
где X обозначает амино- или -O-алкил группу (с 1 - 6 С-атомами в алкиле) и последние, в случае необходимости in situ, превращают с соответствующими производными анилина формулы III
где R3 имеет указанные в пп.1 - 3 или 5 значения, или с их солями до соединений формулы I и/или что в соединения формулы I один или несколько остаток (остатков) превращают в один или несколько других остаток (остатков), или соединение формулы II в присутствии основания из группы бутил- или метиллития превращают с арил-изоцианатом.9. The method of producing compounds in PP.1 to 4, characterized in that the compounds of General formula II
where R 1 and R 2 have the meanings indicated in paragraphs 1 - 3 or 5, are converted with formaldehyde-giving groups from the group of triazine, dimethylformamide, dimethylformamide dimethyl acetal, Goldt's reagent, formic acid chloride, formamide or alkyl derivatives of formamide with 1 - 6 C- atoms in alkyl or with compounds of the group of trialkyl orthoformates, preferably trimethyl orthoformate, to compounds of the general formula IIa
where X denotes an amino or -O-alkyl group (with 1-6 C-atoms in the alkyl) and the latter, if necessary in situ, is converted with the corresponding aniline derivatives of the formula III
where R 3 has the values specified in paragraphs.1 - 3 or 5, or with their salts to the compounds of formula I and / or that into the compounds of formula I, one or more residue (s) is converted into one or more other residue (s), or a compound of formula II in the presence of a base from the group of butyl or methyl lithium is converted with an aryl isocyanate.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19518082A DE19518082A1 (en) | 1995-05-17 | 1995-05-17 | 4 (-Arylaminomethylene) -2,4-dihydropyrazol-3-one |
DE19518082.8 | 1995-05-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU96109192A true RU96109192A (en) | 1998-08-20 |
RU2180659C2 RU2180659C2 (en) | 2002-03-20 |
Family
ID=7762136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU96109192/04A RU2180659C2 (en) | 1995-05-17 | 1996-05-16 | Their synthesis and pharmaceutical composition |
Country Status (22)
Country | Link |
---|---|
US (1) | US5869516A (en) |
EP (1) | EP0743304B1 (en) |
JP (1) | JP3996656B2 (en) |
KR (1) | KR100413154B1 (en) |
CN (1) | CN1066138C (en) |
AT (1) | ATE235469T1 (en) |
AU (1) | AU713042B2 (en) |
CA (1) | CA2176649C (en) |
CZ (1) | CZ291572B6 (en) |
DE (2) | DE19518082A1 (en) |
DK (1) | DK0743304T3 (en) |
ES (1) | ES2192588T3 (en) |
HU (1) | HUP9601328A3 (en) |
NO (1) | NO306777B1 (en) |
PL (1) | PL186049B1 (en) |
PT (1) | PT743304E (en) |
RU (1) | RU2180659C2 (en) |
SI (1) | SI0743304T1 (en) |
SK (1) | SK284295B6 (en) |
TW (1) | TW349093B (en) |
UA (1) | UA59330C2 (en) |
ZA (1) | ZA963918B (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19518082A1 (en) * | 1995-05-17 | 1996-11-21 | Merck Patent Gmbh | 4 (-Arylaminomethylene) -2,4-dihydropyrazol-3-one |
DE19642284A1 (en) * | 1996-10-14 | 1998-04-16 | Merck Patent Gmbh | Pyrazolinones for the treatment of erectile dysfunction |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
CA2238283C (en) | 1997-05-30 | 2002-08-20 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions |
US5858694A (en) * | 1997-05-30 | 1999-01-12 | Cell Pathways, Inc. | Method for identifying compounds for inhibition of cancerous lesions |
US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
DE19807423A1 (en) * | 1998-02-21 | 1999-08-26 | Hoechst Marion Roussel De Gmbh | New isoindolone derivatives useful as soluble guanylate cyclase activators for treating cardiovascular disorders, asthma, renal insufficiency, diabetes, cirrhosis or cognitive dysfunction |
US6294558B1 (en) | 1999-05-31 | 2001-09-25 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
TNSN99111A1 (en) * | 1998-06-11 | 2005-11-10 | Pfizer | NOVEL SULFONYLBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US6727238B2 (en) * | 1998-06-11 | 2004-04-27 | Pfizer Inc. | Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6130053A (en) * | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6025394A (en) | 1999-01-29 | 2000-02-15 | Cell Pathways, Inc. | Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
US6555547B1 (en) | 2000-02-28 | 2003-04-29 | Cell Pathways, Inc. | Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative |
US6569638B1 (en) | 2000-03-03 | 2003-05-27 | Cell Pathways, Inc | Method for screening compounds for the treatment of neoplasia |
RU2379292C2 (en) * | 2003-04-18 | 2010-01-20 | Мемори Фармасьютиклз Корпорейшн | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
EP1799673A1 (en) * | 2004-10-15 | 2007-06-27 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
US8506934B2 (en) | 2005-04-29 | 2013-08-13 | Robert I. Henkin | Methods for detection of biological substances |
US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
WO2007044950A2 (en) * | 2005-10-12 | 2007-04-19 | Sicor, Inc. | Crystalline forms of docetaxel and processes for their preparation |
EP1940389A2 (en) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
CN101355876B (en) | 2005-11-09 | 2012-09-05 | 康宾纳特克斯公司 | Compositions for the eye adminstration |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP1991212A1 (en) * | 2006-03-08 | 2008-11-19 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
MX2008014320A (en) * | 2006-05-09 | 2009-03-25 | Braincells Inc | 5 ht receptor mediated neurogenesis. |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
EP2068872A1 (en) * | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
EP2066355A2 (en) * | 2006-09-19 | 2009-06-10 | Braincells, Inc. | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8293489B2 (en) | 2007-01-31 | 2012-10-23 | Henkin Robert I | Methods for detection of biological substances |
EP2002835A1 (en) * | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2000176A1 (en) * | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
US8580801B2 (en) * | 2008-07-23 | 2013-11-12 | Robert I. Henkin | Phosphodiesterase inhibitor treatment |
EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166008A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP2305679A1 (en) | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
EP2903619B1 (en) | 2012-10-05 | 2019-06-05 | Robert I. Henkin | Phosphodiesterase inhibitors for treating taste and smell disorders |
US9862708B2 (en) | 2014-02-14 | 2018-01-09 | Tempest Therapeutics, Inc. | Pyrazolone compounds and uses thereof |
US10598672B2 (en) | 2014-02-18 | 2020-03-24 | Cyrano Therapeutics, Inc. | Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905997A (en) * | 1974-06-21 | 1975-09-16 | Warner Lambert Co | 3-Aryl-5-oxo-2-pyrazoline-4-carboxanilides and process therefor |
US4355159A (en) * | 1979-05-23 | 1982-10-19 | Ciba-Geigy Corporation | Nickel complex pigments of azines |
US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
DK169672B1 (en) * | 1985-05-20 | 1995-01-09 | Mitsubishi Chem Ind | Pharmaceutical preparations containing pyrazolone derivatives as active ingredient and the use of pyrazolone derivatives for the preparation of pharmaceutical preparations |
US5162528A (en) * | 1986-12-17 | 1992-11-10 | Bayer Aktiengesellschaft | Herbicidal and fungicidal agents based on substituted pyrazolin-5-one derivatives |
DE3728278A1 (en) * | 1986-12-17 | 1988-06-23 | Bayer Ag | HERBICIDES AND FUNGICIDES ON THE BASIS OF SUBSTITUTED PYRAZOLIN-5-ON DERIVATIVES |
US4880804A (en) * | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
GB9119704D0 (en) * | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
DE4130833A1 (en) * | 1991-09-17 | 1993-03-18 | Bayer Ag | DIARYLPYRAZOLINONE |
DE19518082A1 (en) * | 1995-05-17 | 1996-11-21 | Merck Patent Gmbh | 4 (-Arylaminomethylene) -2,4-dihydropyrazol-3-one |
-
1995
- 1995-05-17 DE DE19518082A patent/DE19518082A1/en not_active Withdrawn
-
1996
- 1996-03-18 TW TW085103221A patent/TW349093B/en active
- 1996-05-09 SK SK589-96A patent/SK284295B6/en unknown
- 1996-05-10 AT AT96107518T patent/ATE235469T1/en not_active IP Right Cessation
- 1996-05-10 DE DE59610254T patent/DE59610254D1/en not_active Expired - Lifetime
- 1996-05-10 DK DK96107518T patent/DK0743304T3/en active
- 1996-05-10 ES ES96107518T patent/ES2192588T3/en not_active Expired - Lifetime
- 1996-05-10 PT PT96107518T patent/PT743304E/en unknown
- 1996-05-10 EP EP96107518A patent/EP0743304B1/en not_active Expired - Lifetime
- 1996-05-10 SI SI9630609T patent/SI0743304T1/en unknown
- 1996-05-13 UA UA96051861A patent/UA59330C2/en unknown
- 1996-05-13 AU AU52253/96A patent/AU713042B2/en not_active Ceased
- 1996-05-15 CA CA002176649A patent/CA2176649C/en not_active Expired - Fee Related
- 1996-05-15 NO NO961996A patent/NO306777B1/en not_active IP Right Cessation
- 1996-05-15 CN CN96107453A patent/CN1066138C/en not_active Expired - Fee Related
- 1996-05-16 US US08/648,951 patent/US5869516A/en not_active Expired - Lifetime
- 1996-05-16 KR KR1019960016421A patent/KR100413154B1/en not_active IP Right Cessation
- 1996-05-16 PL PL96314286A patent/PL186049B1/en not_active IP Right Cessation
- 1996-05-16 ZA ZA963918A patent/ZA963918B/en unknown
- 1996-05-16 CZ CZ19961421A patent/CZ291572B6/en not_active IP Right Cessation
- 1996-05-16 RU RU96109192/04A patent/RU2180659C2/en not_active IP Right Cessation
- 1996-05-16 HU HU9601328A patent/HUP9601328A3/en unknown
- 1996-05-17 JP JP14644696A patent/JP3996656B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU96109192A (en) | 4 (-Arylaminomethyl) -2,4-DIHYDRO-PYRAZOL-3-ONE, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION, METHOD FOR ITS OBTAINING, METHOD OF TREATING DISEASES | |
KR960041166A (en) | 4- (arylaminomethylene) -2,4-dihydro-3-pyrazolone | |
RU2017142159A (en) | DIARILHIDANTOINS | |
DE2758762A1 (en) | PHOTOGRAPHIC NEGATIVE IMAGE SILVER HALOGENIDE MATERIAL | |
KR900001694A (en) | Compounds | |
DK426889D0 (en) | N-SUBSTITUTED 2- (PHENYL OR BICYCLO (2.2.1) HEPT-2-YL) OXYNICOTINAMIDE COMPOUNDS, SUCH CONNECTIONS FOR THERAPEUTIC USE AND THEIR USE FOR THE PREPARATION OF THE MEDICINAL PRODUCTS FOR THE USE OF THE MEDICINAL PRODUCTS | |
RU2006112593A (en) | 2, 4-DI (HETERO) ARILAMINOPYRIMIDINE DERIVATIVES AS ZAP-70 AND / OR SYK INHIBITORS | |
ATE163012T1 (en) | N-SUBSTITUTED 4-PYRIMIDINAMINES AND - PYRIMIDINDIAMINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS | |
DE69929689D1 (en) | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF HEART FAILURE AND OTHER DISEASES | |
CA2252907A1 (en) | Novel 2,3 disubstituted-4(3h)-quinazolinones | |
SK281317B6 (en) | Use of isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides for preparing drugs | |
DE69636670D1 (en) | BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS GABA A RECEPTOR COMPLEX MODULATORS | |
ATE180779T1 (en) | N-ARYLHETEROARYLALKYLIMIDAZOLE-2-ONE COMPOUNDS FOR THE TREATMENT OF CIRCULATION DISORDERS | |
KR880007460A (en) | 3-hetero-substituted-N-benzyl-indole | |
KR910009669A (en) | Substituted N- (imidazolyl) alkyl Alanine Derivatives | |
KR880003920A (en) | Pyridazinone derivatives | |
Wong et al. | Identification of a dihydropyridine as a potent α1a adrenoceptor-selective antagonist that inhibits phenylephrine-induced contraction of the human prostate | |
Rolfs et al. | Versatile novel syntheses of imidazoles | |
NO961404L (en) | 4 indolylpiperazinyl derivatives | |
KR890016018A (en) | 6-oxo-pyridazine derivatives, preparation method of these compounds and pharmaceutical products containing the same | |
KR920006337A (en) | Heteroaryl methyl benzene | |
US4610991A (en) | Antihypertensive pyridylaminobenzamide compounds | |
JPH10316654A (en) | 2-aminopyrrole derivative and its production | |
DE59309898D1 (en) | 4-OXO-AZETIDINE-2-SULFONIC ACID AND ITS SALTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | |
KR790001682B1 (en) | Process for producing hetero cyclic compounds |